Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4871153
Max Phase: Preclinical
Molecular Formula: C54H74F12N12O14
Molecular Weight: 887.14
Molecule Type: Unknown
Associated Items:
ID: ALA4871153
Max Phase: Preclinical
Molecular Formula: C54H74F12N12O14
Molecular Weight: 887.14
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC1CCN(CCCCC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C46H70N12O6.4C2HF3O2/c1-31(42(61)55-38(15-7-9-23-47)45(64)52-32(2)59)51-44(63)37(16-11-24-50-46(48)49)53-34-21-28-56(29-22-34)25-10-8-12-33-19-26-57(27-20-33)30-41(60)58-39-17-5-3-13-35(39)43(62)54-36-14-4-6-18-40(36)58;4*3-2(4,5)1(6)7/h3-6,13-14,17-18,31,33-34,37-38,53H,7-12,15-16,19-30,47H2,1-2H3,(H,51,63)(H,54,62)(H,55,61)(H4,48,49,50)(H,52,59,64);4*(H,6,7)/t31-,37-,38-;;;;/m0..../s1
Standard InChI Key: UZRFNJPYRIBTTC-YBRRKNFDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 887.14 | Molecular Weight (Monoisotopic): 886.5541 | AlogP: 2.27 | #Rotatable Bonds: 22 |
Polar Surface Area: 260.21 | Molecular Species: BASE | HBA: 11 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.58 | CX Basic pKa: 12.00 | CX LogP: -0.51 | CX LogD: -7.03 |
Aromatic Rings: 2 | Heavy Atoms: 64 | QED Weighted: 0.05 | Np Likeness Score: -0.30 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):